TABLE I.

Indications set out in Canadian product monographs for anti–epidermal growth factor receptor (egfr) therapies in metastatic colorectal cancer (mcrc)

Cetuximab	Used in combination with irinotecan for the treatment of egfr-expressing mcrc in patients who are refractory to other irinotecan-based chemotherapy regimens.
	Used as a single agent for the treatment of egfr-expressing mcrc in patients who are intolerant to irinotecan-based chemotherapy.
	Used as a single agent for the treatment of patients with egfr-expressing mcrc after failure of both irinotecan- and oxaliplatin-based regimens and after administration of a fluoropyrimidine, where the tumours have a wild-type (non-mutated) Kirsten rat sarcoma (kras) gene.
Panitumumab	Used as monotherapy for the treatment of patients with egfr-expressing mcrc with non-mutated (wild-type) kras after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.